Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins

Open access
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, Florence, Sun, Nan, Bantis, Leonidas E., Muller, David C., Li, Peng, Taguchi, Ayumu, Dhillon, Dilsher, Kundnani, Deepali L., Patel, Nikul J., Yan, Qingxiang, Byrnes, Graham, Moons, Karel G. M., Tjønneland, Anne, Panico, Salvatore, Agnoli, Claudia, Vineis, Paolo, Palli, Domenico, Bueno-de-Mesquita, Bas, Peeters, Petra H., Agudo, Antonio, Huerta, Jose M., Dorronsoro, Miren, Barranco, Miguel Rodriguez, Ardanaz, Eva, Travis, Ruth C., Byrne, Karl Smith, Boeing, Heiner, Steffen, Annika, Kaaks, Rudolf, Hüsing, Anika, Trichopoulou, Antonia, Lagiou, Pagona, La Vecchia, Carlo, Severi, Gianluca, Boutron-Ruault, Marie-Christine, Sandanger, Torkjel M., Weiderpass, Elisabete, Nøst, Therese H., Tsilidis, Kostas, Riboli, Elio, Grankvist, Kjell, Johansson, Mikael, Goodman, Gary E., Feng, Ziding, Brennan, Paul, Johansson, Mattias, Hanash, Samir M. · 2018 · JAMA Oncology

Abstract

Importance: There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. Objective: To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Design, Setting, and Participants: Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Main Outcomes and Measures: Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). Results: In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 compared with 0.43 for the smoking model. Conversely, at an overall sensitivity of 0.42, based on the US Preventive Services Task Force screening criteria, the integrated risk prediction model yielded a specificity of 0.95 compared with 0.86 for the smoking model. Conclusions and Relevance: This study provided a proof of principle in showing that a panel of circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2018.2078

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 169

Metadata

Authors
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., Dhillon, D., Kundnani, D. L., Patel, N. J., Yan, Q., Byrnes, G., Moons, K. G. M., Tjønneland, A., Panico, S., Agnoli, C., Vineis, P., Palli, D., Bueno-de-Mesquita, B., Peeters, P. H., Agudo, A., Huerta, J. M., Dorronsoro, M., Barranco, M. R., Ardanaz, E., Travis, R. C., Byrne, K. S., Boeing, H., Steffen, A., Kaaks, R., Hüsing, A., Trichopoulou, A., Lagiou, P., La Vecchia, C., Severi, G., Boutron-Ruault, M.-C., Sandanger, T. M., Weiderpass, E., Nøst, T. H., Tsilidis, K., Riboli, E., Grankvist, K., Johansson, M., Goodman, G. E., Feng, Z., Brennan, P., Johansson, M., & Hanash, S. M.
Venue
JAMA Oncology
Published
2018-10-11
Volume
4
Issue
10
Pages
e182078
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2862606086
Cited by
169
References
2
FWCI
5.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. https://app.cochat.ai/papers/10.1001/jamaoncol.2018.2078
The paper
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., Dhillon, D., Kundnani, D. L., Patel, N. J., Yan, Q., Byrnes, G., Moons, K. G. M., Tjønneland, A., Panico, S., Agnoli, C., Vineis, P., Palli, D., Bueno-de-Mesquita, B., . . . Hanash, S. M. (2018). Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.2078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.